Companies in #Migraine

Biohaven is a clinical-stage biopharmaceutical company developing therapies for neurological and neuropsychiatric diseases. Following the spin-off of its commercial migraine portfolio to Pfizer, Biohaven is advancing next-generation neuroscience programs including IGF-1 targeted therapies and rare disease programs.

Lundbeck is a Danish specialty pharmaceutical company focused on central nervous system (CNS) disorders including depression, schizophrenia, Parkinson's disease, and migraine. Vyepti (eptinezumab), its CGRP-targeting migraine therapy, is a key growth asset.

Mentari is a biotechnology company focused on developing therapies for migraine and related neurological disorders.

Slate Medicines is a clinical-stage biotechnology company developing anti-PACAP therapeutics for migraine and headache disorders. The company launched in 2026 with a $130M Series A to advance its lead program SLTE-1009 and other PACAP-pathway candidates, joining a competitive class of next-generation migraine developers seeking to challenge the CGRP inhibitor standard of care.

Public biopharma (Nasdaq: SUPN) developing and commercializing CNS therapeutics across epilepsy, migraine, Parkinson's disease, ADHD and postpartum depression; agreed to an all-stock merger with Indivior in 2026.

Theranica is a digital therapeutics company developing FDA-cleared neuromodulation devices for migraine and other neurological conditions. Nerivio, its wearable non-invasive vagus nerve stimulation device, became the first neuromodulation product to reach more than half of the U.S. insured population.